Difference between revisions of "Bone sarcoma"
Jump to navigation
Jump to search
m |
m |
||
| Line 9: | Line 9: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
| − | |||
| − | |||
=Guidelines= | =Guidelines= | ||
==ESMO== | ==ESMO== | ||
| Line 22: | Line 19: | ||
*Mesenchymal chondrosarcoma has been treated with [[Ewing's sarcoma|Ewing's sarcoma regimens]] | *Mesenchymal chondrosarcoma has been treated with [[Ewing's sarcoma|Ewing's sarcoma regimens]] | ||
*Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]] | *Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]] | ||
| + | |||
| + | =Ewing's sarcoma, all lines of therapy= | ||
| + | *Please see the [[Ewing's sarcoma|dedicated Ewing's sarcoma page]]. | ||
| + | |||
| + | =Giant-cell tumor of bone, all lines of therapy= | ||
| + | ==Denosumab monotherapy {{#subobject:65e2b|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | |||
| + | ===Regimen {{#subobject:f50a28|Variant=1}}=== | ||
| + | {| border="1" style="text-align:center;" !align="left" | ||
| + | |'''Study''' | ||
| + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
| + | |- | ||
| + | |[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext Thomas et. al 2010] | ||
| + | |style="background-color:#EEEE00"|Phase II | ||
| + | |- | ||
| + | |} | ||
| + | ====Primary therapy==== | ||
| + | *[[Denosumab (Xgeva)]] as follows: | ||
| + | **Cycle 1: 120 mg SC once per day on days 1, 8, 15 | ||
| + | **Cycle 2 onwards: 120 mg SC once on day 1 | ||
| + | |||
| + | ====Supportive medications==== | ||
| + | *Calcium 500 mg PO once per day | ||
| + | *Vitamin D 400 IU PO once per day | ||
| + | |||
| + | '''28-day cycles, given until complete tumor resection, progression of disease, or patient choice''' | ||
| + | |||
| + | ===References=== | ||
| + | # Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20149736 PubMed] | ||
=Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy= | =Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy= | ||
*Malignant fibrous histiocytoma (MFH) of bone has been treated with [[Osteosarcoma|osteosarcoma regimens]] | *Malignant fibrous histiocytoma (MFH) of bone has been treated with [[Osteosarcoma|osteosarcoma regimens]] | ||
| + | |||
| + | =Osteosarcoma, all lines of therapy= | ||
| + | *Please see the [[osteosarcoma|dedicated osteosarcoma page]]. | ||
[[Category:Bone cancer regimens]] | [[Category:Bone cancer regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Sarcomas]] | [[Category:Sarcomas]] | ||
Revision as of 13:29, 19 October 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
0 regimens on this page
0 variants on this page
|
Guidelines
ESMO
NCCN
Chondrosarcoma, all lines of therapy
- No standard chemotherapy for grades 1 to 3 conventional chondrosarcoma
- Mesenchymal chondrosarcoma has been treated with Ewing's sarcoma regimens
- Dedifferentiated chondrosarcoma has been treated with osteosarcoma regimens
Ewing's sarcoma, all lines of therapy
- Please see the dedicated Ewing's sarcoma page.
Giant-cell tumor of bone, all lines of therapy
Denosumab monotherapy
| back to top |
Regimen
| Study | Evidence |
| Thomas et. al 2010 | Phase II |
Primary therapy
- Denosumab (Xgeva) as follows:
- Cycle 1: 120 mg SC once per day on days 1, 8, 15
- Cycle 2 onwards: 120 mg SC once on day 1
Supportive medications
- Calcium 500 mg PO once per day
- Vitamin D 400 IU PO once per day
28-day cycles, given until complete tumor resection, progression of disease, or patient choice
References
- Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. link to original article contains verified protocol PubMed
Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy
- Malignant fibrous histiocytoma (MFH) of bone has been treated with osteosarcoma regimens
Osteosarcoma, all lines of therapy
- Please see the dedicated osteosarcoma page.